PDGFRA
Biomarker
PDGFRA mutations are oncogenic drivers in gastrointestinal stromal tumors. Specific variants inform targeted treatment selection.
Approvals
1
Indications
1
Therapies
1
Mapped tests
1
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Indication-specific approvals
Approvals where PDGFRA is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Gastrointestinal Stromal Tumors (GIST) Solid Tumor · GIST |
|
Tumor-agnostic approvals
Approvals defined at the solid tumor level where PDGFRA is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report PDGFRA as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Test
therascreen PDGFRA RGQ PCR Kit
QIAGEN GmbH
Method
PCR
Specimen
Tissue (FFPE)
Reports PDGFRA as part of its biomarker panel.
1 approvalView test profile →